Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-07-19 Share Issue/Capital Cha…
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated July 19, 2019, announcing an extension to the subscription period for a directed share issue related to a convertible loan. This action directly concerns the company's capital structure, fundraising, and issuance of new shares (Series B shares). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). While it involves shares, it is an announcement about a financing event (convertible loan conversion/share issue) rather than a routine buyback (POS) or a general share change (SHA). It is not a full 10-K, IR, or ER, but a specific corporate action announcement.
2019-07-19 English
Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development AB regarding a portfolio company's clinical trial progress. It is under 5,000 characters and concludes with an 'Attachment' link to the press release itself, which is a classic indicator of a Report Publication Announcement (RPA) or a general regulatory announcement. Since it is a corporate news update that does not fit into specific financial reporting categories like 10-K or IR, and functions as a general announcement, it is classified as a Regulatory Filing (RNS).
2019-07-09 English
Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development AB regarding a portfolio company's clinical trial progress. It is under 5,000 characters and concludes with an 'Attachment' link to the press release itself, which is a classic indicator of a Report Publication Announcement (RPA) or a general regulatory announcement. Since it is a corporate news update that does not fit into specific financial reporting categories like 10-K or IR, and functions as a general announcement, it is classified as a Regulatory Filing (RNS).
2019-07-09 English
Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development AB regarding a portfolio company's clinical trial progress. It is under 5,000 characters and concludes with an 'Attachment' link to the press release itself, which is a classic indicator of a Report Publication Announcement (RPA) or a general regulatory announcement. Since it is a corporate news update that does not fit into specific financial reporting categories like 10-K or IR, and functions as a general announcement, it is classified as a Regulatory Filing (RNS).
2019-07-09 English
Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
Regulatory Filings Classification · 1% confidence The document is a press release dated July 9, 2019, announcing that Karolinska Development's portfolio company, Dilafor AB, has enrolled the first subject in a Phase 2b study for tafoxiparin. This announcement details clinical trial progress, which is a form of corporate development news. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement about a specific corporate event (clinical trial progress) that doesn't fit the other specific categories (like M&A, Financing, or Management changes), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, or potentially as a general corporate update. Given the options, RNS is the most appropriate fallback for a press release detailing operational/clinical progress.
2019-07-09 English
Karolinska Development offentliggör prospekt avseenderiktad nyemission till Bolagets konvertibelinnehavare
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that the prospectus for a directed new share issue (nyemission) to convertible holders has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The core subject is a financing activity involving the issuance of new shares/securities. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus, the document itself is the announcement of this corporate action, not the full prospectus or a general regulatory filing (RNS). It is more specific than RNS and more focused on capital structure change than a general ER or IR.
2019-07-05 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.